Cargando…

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

OBJECTIVE: The clinical significance of polymorphisms in the interleukin-28B gene encoding interferon (IFN)-λ3, which has antiviral effects, is known in chronic HCV but not in HBV infection. Thus, we measured IFN-λ3 levels in patients with HBV and investigated its clinical significance and associati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murata, Kazumoto, Asano, Mai, Matsumoto, Akihiro, Sugiyama, Masaya, Nishida, Nao, Tanaka, Eiji, Inoue, Taisuke, Sakamoto, Minoru, Enomoto, Nobuyuki, Shirasaki, Takayoshi, Honda, Masao, Kaneko, Shuichi, Gatanaga, Hiroyuki, Oka, Shinichi, Kawamura, Yuki I, Dohi, Taeko, Shuno, Yasutaka, Yano, Hideaki, Mizokami, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868296/ https://www.ncbi.nlm.nih.gov/pubmed/27789659 http://dx.doi.org/10.1136/gutjnl-2016-312653

Ejemplares similares

Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance
por: Meng, Chao-Yang, et al.
Publicado: (2023)

Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
por: Svicher, Valentina, et al.
Publicado: (2021)

Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
por: Amaddeo, Giuliana, et al.
Publicado: (2015)

PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF
por: Li, Jiang, et al.
Publicado: (2022)

Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection
por: Li, Haijun, et al.
Publicado: (2018)

TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection
por: Heim, Kathrin, et al.
Publicado: (2021)

Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo
por: Allweiss, Lena, et al.
Publicado: (2022)

Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure
por: Allweiss, Lena, et al.
Publicado: (2023)

HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation
por: Yuan, Lunzhi, et al.
Publicado: (2019)

Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients
por: Zhang, Chao, et al.
Publicado: (2023)

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
por: Martin, Perrine, et al.
Publicado: (2015)

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C
por: Masaki, Naohiko, et al.
Publicado: (2014)

The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
por: Lemoine, Maud, et al.
Publicado: (2016)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro
por: Rossi, Marzia, et al.
Publicado: (2023)

Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target
por: Verrier, Eloi R, et al.
Publicado: (2023)

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
por: Janssen, Harry L A, et al.
Publicado: (2023)

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study
por: Kimura, Masamichi, et al.
Publicado: (2022)

Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients
por: Murata, Kazumoto, et al.
Publicado: (2013)

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
por: Watanabe, Tsunamasa, et al.
Publicado: (2013)

Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China
por: Liu, Mei, et al.
Publicado: (2022)

Understanding IFNλ in rheumatoid arthritis
por: de Groen, Rik A, et al.
Publicado: (2014)

Prevalence and clinical correlates of insomnia symptoms and their association with quality of life in Chinese patients with HBV-related liver disease
por: Zhao, Jing, et al.
Publicado: (2021)

Association between lymphocyte-to-monocyte ratio (LMR) and the mortality of HBV-related liver cirrhosis: a retrospective cohort study
por: Zhang, Jie, et al.
Publicado: (2015)

Effect of physical exercise on sarcopaenia in patients with overt hepatic encephalopathy: a study protocol for a randomised controlled trial
por: Yoh, Kazunori, et al.
Publicado: (2017)

IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies
por: Duong, Francois H.T., et al.
Publicado: (2014)

IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes
por: Egli, Adrian, et al.
Publicado: (2018)

Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial
por: Wang, Lu, et al.
Publicado: (2021)

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

Monocytes differentiated into macrophages and dendritic cells in the presence of human IFN‐λ3 or IFN‐λ4 show distinct phenotypes
por: De, Manjarika, et al.
Publicado: (2020)

Distinct molecular phenotypes involving several human diseases are induced by IFN-λ3 and IFN-λ4 in monocyte-derived macrophages
por: De, Manjarika, et al.
Publicado: (2022)

Interferon (IFN)-λ Takes the Helm: Immunomodulatory Roles of Type III IFNs
por: Zanoni, Ivan, et al.
Publicado: (2017)

Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
por: Sherstoboev, E. Yu., et al.
Publicado: (2022)

Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients
por: Grzegorzewska, Alicja E., et al.
Publicado: (2017)

Mean arterial pressure drop is an independent risk factor of hepatorenal syndrome in patients with HBV-ACLF
por: Zheng, Xingrong, et al.
Publicado: (2022)

IFN‐λ4 inhibits HIV infection of macrophages through signalling of IFN‐λR1/IL‐10R2 receptor complex
por: Su, Qi‐Jian, et al.
Publicado: (2018)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages
por: Wang, Xu, et al.
Publicado: (2017)

Functions of IFNλs in Anti-Bacterial Immunity at Mucosal Barriers
por: Alphonse, Noémie, et al.
Publicado: (2022)

IFNλ: balancing the light and dark side in pulmonary infection
por: Antos, Danielle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jqs9pqjncpna47eisqcaqpv2vq